Inclusion Criteria:

1. Age> or = 18 and < 75 ans

2. WHO Status 0, 1 and 2

3. Enteral or parenteral feeding (> or = 1500 KCal) planned before the start of
treatment

4. Histologically proven carcinoma of the oesophagus

5. Histological Types: adenocarcinomas and epidermoid carcinomas

6. T3, N0-N1-N2-N3, M0 ou M1a

7. T1-T2, N0-N1-N2-N3, M0 or M1a with a contra-indication for surgery

8. Absence of trachea-oesophageal fistula

9. Written informed consent

10. Woman under appropriate contraception

11. Patient able to understand and complete, with help if necessary, a quality of life
questionnaire

Exclusion Criteria:

1. Evolutive heart failure or myocardial necrosis for less than 6 months

2. Myocardial infarction of more than 6 months with ischemic sequelae on myocardial
scintigraphy.

3. Patient cannot absorb at least 1500kcal/j before and/or during treatment

4. Left heart failure.

5. Stage II to IV arteriopathy in the Leriche and Fontaine classification

6. Creatinine > or = 1.25x N

7. PNN < 1,5.109 /l

8. Platelets < 100. 109 /l

9. Albumin < 30g/l

10. TP < 60%

11. VEMS < 1l

12. History of cancer (except baso-cellular cutaneous epithelioma or in situ epithelioma
of the cervix) that has relapsed in the 5 years preceding recruitment for the trial

13. Patient already enrolled in another therapeutic trial with an experimental molecule

14. Women who are pregnant or likely to be so, or who are breastfeeding

15. People who are in custody or under guardianship

16. Impossibility to adhere to the medical follow up for the trial for
geographical,social or psychiatric reasons.

17. Presence of a history of radiotherapy to the chest or upper abdomen for another
tumour

18. Peripheral neuropathy > or = grade 1 (CTC v3.0)